Conjoint Professor
Professor Michelle Haber
1984 PhD University of New South Wales
1978-79 PhD qualifying program University of New South Wales
1978 BSc (Psych) Honours Class 1, University Medal University of New South Wales
2008 D.Sc. honaris causa University of New South Wales
medicine-health
Sch Women's&Children's Health
Professor Michelle Haber obtained her PhD at UNSW in 1984, and subsequently undertook postdoctoral studies at Hadassah Hebrew University, Israel and Albert Einstein College of Medicine, New York. She was appointed as the Director of the Children's Cancer Institute (CCI) in 2000, and then Executive Director in 2003, where she is the Co-Head of CCI’s Molecular Targets and Cancer Therapeutics Theme and also heads the Experimental Therapeutics Program.
Michelle’s research is focused on developing novel approaches to treating refractory childhood cancer through identifying molecular targets that drive cancer growth and development, developing new drugs to inhibit the action of these targets, and combining existing and new drug treatments into novel therapeutic approaches that can be rapidly translated into national and international clinical trials.
Phone
+61 2 7209 6709
E-mail
Location
Children's Cancer Institute
Lowy Cancer Research Centre, UNSW Australia
PO Box 81 Randwick 2031 Australia
- Publications
- Awards
- Grants
- Media
Publications
Awards
Honours:
2007 Member of the Order of Australia (AM) for services to science in the field of research into childhood cancer, to scientific education and to the community
2010-12 President, Advances in Neuroblastoma Research Association.
2008 Degree of Doctor of Science, honoris causa, in recognition of eminent service to the community, University of New South Wales
2015 Inaugural Fellow, Australian Academy of Health and Medical Sciences
2020 Invited Speaker, American Association for Cancer Research, Presidential Select Symposium, San Diego, CA, USA
Awards:
2011 Winner - NSW Science and Engineering Award for Biomedical Sciences
2012 Winner - Cancer Institute NSW Premier’s Award for Excellence in Translational Cancer Research
2013 Finalist - NSW Health Jamie Callachor Eureka Prize for Medical Research Translation
2014 Winner - Best Translational Research Presentation, Advances in Neuroblastoma Research Congress, Cologne, Germany
2014 Winner - Cancer Institute NSW’s Premier’s Award for Outstanding Cancer Researcher of the Year
2015 Finalist - The Australian Innovation Challenge Award, for pioneering work in improving the survival rates of children with acute lymphoblastic leukaemia
2018 Finalist - CSIRO Eureka Prize for Leadership in Innovation and Science
Grants
- 2020-2024 MRFF Emerging Priorities and Consumer Driven Research initiative EPCD000015) 'ZERO Childhood Cancer National Precision Medicine Program'
- 2020-2023 Australian Cancer Research Foundation 'The ACRF Child Cancer Liquid Biopsy Program'
- 2020-2023 Neuroblastoma Australia ‘MYC inhibitors to potentiate CART cell therapy
- 2020-2023 Cancer Australia/ The Kids Cancer Project ‘Enhanced polyamine depletion as a novel therapy for aggressive cancers
- 2019- 2021 Cancer Australia- 'Targeting the NAD pathway as a new therapeutic strategy for high-risk leukaemia in children'
- 2019- 2023 APP1159004 NHMRC Partnerships Project- 'The economic impact of precision medicine in high risk and aggressive childhood cancer'
- 2018-2022 Children’s Cancer Foundation- 'SIOPEN neuroblastoma clinical trials in Australia and New Zealand'
- 2018-2021 Children’s Cancer Foundation- 'Leveraging the SIOPEN High risk 2.0 clinical trial for high-risk neuroblastoma to understand relapse, improve residual disease detection and develop pre-clinical testing models for high-risk neuroblastoma'
-
2018 Cancer Australia/Medical Research Future Fund Australian Brain Cancer Mission- 'Zero Childhood Brain'
-
2019 Tour de Cure Foundation - 'A personalised medicine approach to the treatment of acute myeloid leukaemia in children'
-
2018 REG181200 – Cancer Institute NSW Research Equipment Grant- 'Australia’s first deformability cytometer – a novel tool for cancer mechanobiology and diagnosis'
-
2018- 2020 APP1136278 – NHMRC Development Grant- 'Multidrug Resistance Protein 1 inhibitors to sensitise cancers to chemotherapy'
-
2018- 2022 APP1132608 – NHMRC Program Grant- 'More effective therapeutic targeting of high risk childhood cancer: Neuroblastoma as a model'